GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00160557 | Cervix | CC | Wnt signaling pathway | 98/2311 | 444/18723 | 4.82e-09 | 4.65e-07 | 98 |
GO:01987387 | Cervix | CC | cell-cell signaling by wnt | 98/2311 | 446/18723 | 6.16e-09 | 5.58e-07 | 98 |
GO:00301117 | Cervix | CC | regulation of Wnt signaling pathway | 76/2311 | 328/18723 | 3.05e-08 | 2.08e-06 | 76 |
GO:19030349 | Cervix | CC | regulation of response to wounding | 44/2311 | 167/18723 | 6.33e-07 | 2.31e-05 | 44 |
GO:00608287 | Cervix | CC | regulation of canonical Wnt signaling pathway | 58/2311 | 253/18723 | 1.83e-06 | 5.89e-05 | 58 |
GO:00600707 | Cervix | CC | canonical Wnt signaling pathway | 66/2311 | 303/18723 | 2.47e-06 | 7.35e-05 | 66 |
GO:00109757 | Cervix | CC | regulation of neuron projection development | 88/2311 | 445/18723 | 4.26e-06 | 1.09e-04 | 88 |
GO:00310996 | Cervix | CC | regeneration | 46/2311 | 198/18723 | 1.43e-05 | 2.84e-04 | 46 |
GO:00615647 | Cervix | CC | axon development | 89/2311 | 467/18723 | 1.71e-05 | 3.27e-04 | 89 |
GO:00313456 | Cervix | CC | negative regulation of cell projection organization | 39/2311 | 186/18723 | 5.86e-04 | 5.57e-03 | 39 |
GO:00321022 | Cervix | CC | negative regulation of response to external stimulus | 75/2311 | 420/18723 | 5.96e-04 | 5.61e-03 | 75 |
GO:00301784 | Cervix | CC | negative regulation of Wnt signaling pathway | 35/2311 | 170/18723 | 1.52e-03 | 1.17e-02 | 35 |
GO:00015037 | Cervix | CC | ossification | 71/2311 | 408/18723 | 1.67e-03 | 1.28e-02 | 71 |
GO:00487365 | Cervix | CC | appendage development | 35/2311 | 172/18723 | 1.88e-03 | 1.39e-02 | 35 |
GO:00601735 | Cervix | CC | limb development | 35/2311 | 172/18723 | 1.88e-03 | 1.39e-02 | 35 |
GO:00900901 | Cervix | CC | negative regulation of canonical Wnt signaling pathway | 29/2311 | 137/18723 | 2.40e-03 | 1.70e-02 | 29 |
GO:00109775 | Cervix | CC | negative regulation of neuron projection development | 28/2311 | 137/18723 | 4.74e-03 | 2.83e-02 | 28 |
GO:00486782 | Cervix | CC | response to axon injury | 19/2311 | 83/18723 | 5.25e-03 | 3.08e-02 | 19 |
GO:0048679 | Cervix | CC | regulation of axon regeneration | 9/2311 | 29/18723 | 6.49e-03 | 3.61e-02 | 9 |
GO:00302781 | Cervix | CC | regulation of ossification | 24/2311 | 115/18723 | 6.51e-03 | 3.61e-02 | 24 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MEN1 | SNV | Missense_Mutation | novel | c.676N>A | p.Leu226Met | p.L226M | O00255 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A2-A04N-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD |
MEN1 | SNV | Missense_Mutation | | c.1817C>G | p.Ser606Cys | p.S606C | O00255 | protein_coding | deleterious(0.01) | possibly_damaging(0.82) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
MEN1 | SNV | Missense_Mutation | | c.323G>C | p.Arg108Pro | p.R108P | O00255 | protein_coding | tolerated(0.07) | possibly_damaging(0.7) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
MEN1 | SNV | Missense_Mutation | | c.1084G>C | p.Asp362His | p.D362H | O00255 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AC-A6IX-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
MEN1 | SNV | Missense_Mutation | rs377715802 | c.1040N>T | p.Ala347Val | p.A347V | O00255 | protein_coding | deleterious(0) | possibly_damaging(0.726) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MEN1 | SNV | Missense_Mutation | | c.479N>T | p.Ser160Phe | p.S160F | O00255 | protein_coding | tolerated(1) | benign(0.009) | TCGA-BH-A0DK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
MEN1 | SNV | Missense_Mutation | | c.550G>A | p.Glu184Lys | p.E184K | O00255 | protein_coding | deleterious(0) | probably_damaging(0.934) | TCGA-C8-A8HQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MEN1 | deletion | Frame_Shift_Del | | c.1700_1706delNNNNNNN | p.Lys567SerfsTer24 | p.K567Sfs*24 | O00255 | protein_coding | | | TCGA-BH-A18R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MEN1 | deletion | Frame_Shift_Del | | c.225_229delNNNNN | p.Thr76LeufsTer39 | p.T76Lfs*39 | O00255 | protein_coding | | | TCGA-E9-A1N5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
MEN1 | insertion | Frame_Shift_Ins | rs767319284 | c.1561_1562insC | p.Arg521ProfsTer15 | p.R521Pfs*15 | O00255 | protein_coding | | | TCGA-E9-A228-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
4221 | MEN1 | CLINICALLY ACTIONABLE, DNA REPAIR | | CHLORHEXIDINE HYDROCHLORIDE | CHLORHEXIDINE HYDROCHLORIDE | |
4221 | MEN1 | CLINICALLY ACTIONABLE, DNA REPAIR | | FURAFYLLINE | FURAFYLLINE | |
4221 | MEN1 | CLINICALLY ACTIONABLE, DNA REPAIR | | TCMDC-123591 | CHEMBL588234 | |
4221 | MEN1 | CLINICALLY ACTIONABLE, DNA REPAIR | | CYCLIRAMINE MALEATE | CYCLIRAMINE MALEATE | |
4221 | MEN1 | CLINICALLY ACTIONABLE, DNA REPAIR | | METHYLENE BLUE | METHYLENE BLUE | |
4221 | MEN1 | CLINICALLY ACTIONABLE, DNA REPAIR | | TANNIC ACID | TANNIC ACID | |
4221 | MEN1 | CLINICALLY ACTIONABLE, DNA REPAIR | | SJ000029700 | CHEMBL591864 | |
4221 | MEN1 | CLINICALLY ACTIONABLE, DNA REPAIR | | TRIMETREXATE | TRIMETREXATE | |
4221 | MEN1 | CLINICALLY ACTIONABLE, DNA REPAIR | | TCMDC-124518 | CHEMBL527584 | |
4221 | MEN1 | CLINICALLY ACTIONABLE, DNA REPAIR | | TRACAZOLATE | TRACAZOLATE | |